Literature DB >> 17719657

Effective small interfering RNAs targeting matrix and nucleocapsid protein gene inhibit influenza A virus replication in cells and mice.

Hongbo Zhou1, Meilin Jin, Zhengjun Yu, Xiaojuan Xu, Yaping Peng, Haiya Wu, Jinlin Liu, Hu Liu, Shengbo Cao, Huanchun Chen.   

Abstract

RNA interference (RNAi) is a powerful tool to silence gene expression. Small interfering RNA (siRNA)-induced RNA degradation has been recently used as an antivirus agent to inhibit specific virus replication. Here, we showed that several siRNAs specific for conserved regions of influenza virus matrix (M2) and nucleocapsid protein (NP) genes could effectively inhibit expression of the corresponding viral protein. We also evaluated the antiviral potential of these siRNAs targeting M2 and NP of H5N1 avian influenza virus (AIV), which are essential to viral replication. We investigated the inhibitory effect of M2-specific siRNAs and NP-specific siRNAs on influenza A virus (H5N1, H1N1 and H9N2) replication in Madin-Darby canine kidney (MDCK) cells and BALB/c mice. The results showed that treatment with these siRNAs could specifically inhibit influenza A virus replication in MDCK cells (0.51-1.63 TCID(50) reduction in virus titers), and delivery of pS-M48 and pS-NP1383 significantly reduced lung virus titers in the infected mice (16-50-fold reduction in lung virus titers) and partially protected the mice from lethal influenza virus challenge (a survival rate of 4/8 for H1N1 virus-infected mice and 2/8 for H5N1 virus infected mice). Moreover, the treatment of pS-M48 and pS-NP1383 could suppress replication of different subtypes of influenza A viruses, including a H5N1 highly pathogenic avian isolate strain. The results provided a basis for further development of siRNA for prophylaxis and therapy of influenza virus infection in humans and animals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17719657     DOI: 10.1016/j.antiviral.2007.07.002

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  30 in total

Review 1.  Pandemic and seasonal influenza: therapeutic challenges.

Authors:  Matthew J Memoli; David M Morens; Jeffery K Taubenberger
Journal:  Drug Discov Today       Date:  2008-05-15       Impact factor: 7.851

Review 2.  Newer influenza antivirals, biotherapeutics and combinations.

Authors:  Frederick G Hayden
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

3.  Inhibition of encephalomyocarditis virus replication by shRNA targeting 1D and 3AB genes in vitro and in vivo.

Authors:  Juan Bai; Kangfu Jiang; Basit Zeshan; Xianwei Wang; Yufeng Li; Ping Jiang
Journal:  Virus Genes       Date:  2011-11-04       Impact factor: 2.332

4.  Targeted small interfering RNA-immunoliposomes as a promising therapeutic agent against highly pathogenic Avian Influenza A (H5N1) virus infection.

Authors:  Kannika Khantasup; Phikulthong Kopermsub; Kridsada Chaichoun; Tararaj Dharakul
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

Review 5.  Drugs in development for influenza.

Authors:  David A Boltz; Jerry R Aldridge; Robert G Webster; Elena A Govorkova
Journal:  Drugs       Date:  2010-07-30       Impact factor: 9.546

6.  siRNAs targeting PB2 and NP genes potentially inhibit replication of Highly Pathogenic H5N1 Avian Influenza Virus.

Authors:  Padmanava Behera; Shanmugasundaram Nagarajan; Harshad V Murugkar; Semmannan Kalaiyarasu; Anil Prakash; Ragini Gothalwal; Shiv Chandra Dubey; Diwakar D Kulkarni; Chakradhar Tosh
Journal:  J Biosci       Date:  2015-06       Impact factor: 1.826

7.  Emerging Technologies for the Treatment of COVID-19.

Authors:  Hossein Aghamollaei; Rahim Sarvestani; Hamid Bakherad; Hamed Zare; Paul C Guest; Reza Ranjbar; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 8.  Antivirals for influenza: strategies for use in pediatrics.

Authors:  Steven M Smith; John G Gums
Journal:  Paediatr Drugs       Date:  2010-10-01       Impact factor: 3.022

9.  The plasmid constructs producing shRNA corresponding to the conserved 3D polymerase of Foot and Mouth Disease virus protects guinea pigs against challenge virus.

Authors:  Dechamma Hosur Joyappa; Sarika Sasi; Kumar C Ashok; Golla Rama Reddy; Veluvarthy V S Suryanarayana
Journal:  Vet Res Commun       Date:  2008-09-23       Impact factor: 2.459

10.  Effective inhibition of mRNA accumulation and protein expression of H5N1 avian influenza virus NS1 gene in vitro by small interfering RNAs.

Authors:  Hanwei Jiao; Li Du; Yongchang Hao; Ying Cheng; Jing Luo; Wenhua Kuang; Donglin Zhang; Ming Lei; Xiaoxiao Jia; Xiaoru Zhang; Chao Qi; Hongxuan He; Fengyang Wang
Journal:  Folia Microbiol (Praha)       Date:  2012-11-29       Impact factor: 2.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.